First Financial Bankshares Inc Buys 27,726 Shares of Johnson & Johnson $JNJ

Key Points

• First Financial Bankshares Inc increased its holdings in Johnson & Johnson by 4.3%, owning 673,083 shares valued at approximately $111.6 million, making it the bank's 8th largest investment.
• Johnson & Johnson reported earnings of $2.77 per share for the last quarter, exceeding estimates, with revenue reaching $23.74 billion, a year-over-year increase of 5.8%.
• The company recently announced a quarterly dividend of $1.30 per share, translating into an annual yield of 2.9%, with a payout ratio of 55.61%.

First Financial Bankshares Inc grew its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 4.3% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 673,083 shares of the company's stock after purchasing an additional 27,726 shares during the quarter. Johnson & Johnson makes up approximately 2.4% of First Financial Bankshares Inc's portfolio, making the stock its 8th biggest position. First Financial Bankshares Inc's holdings in Johnson & Johnson were worth $111,624,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in JNJ. Highline Wealth Partners LLC grew its holdings in shares of Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after buying an additional 86 shares during the last quarter. Stone House Investment Management LLC bought a new position in shares of Johnson & Johnson during the 1st quarter valued at approximately $47,000. von Borstel & Associates Inc. bought a new stake in shares of Johnson & Johnson during the 1st quarter valued at $49,000. Capital A Wealth Management LLC purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth about $50,000. Finally, Harvest Fund Management Co. Ltd bought a new position in shares of Johnson & Johnson during the first quarter worth $52,000. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Trading Down 0.2%

Shares of NYSE:JNJ traded down $0.35 during midday trading on Wednesday, reaching $177.71. 6,832,001 shares of the company's stock were exchanged, compared to its average volume of 7,666,583. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The stock has a market cap of $427.98 billion, a price-to-earnings ratio of 17.72, a P/E/G ratio of 2.26 and a beta of 0.40. The firm's 50 day simple moving average is $167.02 and its two-hundred day simple moving average is $160.33. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $181.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. The company had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The firm's quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be given a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.9%. Johnson & Johnson's dividend payout ratio is currently 55.61%.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on JNJ. Leerink Partners lowered shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and cut their target price for the company from $169.00 to $153.00 in a report on Tuesday, May 13th. Morgan Stanley raised their target price on shares of Johnson & Johnson from $171.00 to $176.00 and gave the company an "equal weight" rating in a research report on Thursday, July 17th. Guggenheim reaffirmed a "neutral" rating and issued a $167.00 price objective (up from $164.00) on shares of Johnson & Johnson in a research report on Thursday, July 17th. Royal Bank Of Canada raised their price target on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a research report on Thursday, July 17th. Finally, Barclays raised their price objective on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 17th. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have given a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $176.29.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.